Cancer is a complex disease driven by somatic mutations accumulating within a cell's genome, akin to a series of typos in a vast instruction manual.  Advances in genomics have revolutionized our understanding of this genetic basis, allowing us to view each tumour's unique "typographical errors."  Next-generation sequencing (NGS) acts like a high-resolution proofreader, identifying specific mutations driving tumour growth and progression, analogous to pinpointing the critical errors in a document.  This has paved the way for personalized medicine, where treatment strategies are tailored to the individual's specific genetic profile.  Think of it as creating a custom-designed correction fluid, targeting only the problematic mutations instead of applying a broad, potentially damaging correction to the entire manuscript (the patient's body).  This targeted approach, exemplified by therapies such as immune checkpoint inhibitors and kinase inhibitors, promises increased efficacy and reduced toxicity.  However, challenges remain, including the identification of actionable mutations, the complexity of tumour heterogeneity (multiple "errors" in the same document), and the need for cost-effective and accessible NGS technologies. Future research will focus on refining these methods and incorporating additional omics data, creating a truly comprehensive understanding of cancer's genetic landscape and unlocking its therapeutic potential.